These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 10521062)
1. Oral fluoropyrimidines: a closer look at their toxicities. Macdonald JS Am J Clin Oncol; 1999 Oct; 22(5):475-80. PubMed ID: 10521062 [TBL] [Abstract][Full Text] [Related]
2. New options for outpatient chemotherapy--the role of oral fluoropyrimidines. Cunningham D; Coleman R Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541 [TBL] [Abstract][Full Text] [Related]
6. Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer. Cunningham D; James RD Eur J Cancer; 2001 May; 37(7):826-34. PubMed ID: 11313169 [TBL] [Abstract][Full Text] [Related]
7. Oral therapy for colorectal cancer: how to choose. Damjanov N; Meropol NJ Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632 [TBL] [Abstract][Full Text] [Related]
8. Oral versus intravenous fluoropyrimidines for colorectal cancer. Chionh F; Lau D; Yeung Y; Price T; Tebbutt N Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564 [TBL] [Abstract][Full Text] [Related]
9. Oral fluoropyrimidines: are they the equivalent of parenteral infusional 5-fluorouracil? Lokich J Cancer Invest; 2001; 19(8):854-7. PubMed ID: 11768039 [No Abstract] [Full Text] [Related]
10. Oral fluoropyrimidines in the treatment of colorectal cancer. Meropol NJ Eur J Cancer; 1998 Sep; 34(10):1509-13. PubMed ID: 9893621 [TBL] [Abstract][Full Text] [Related]
12. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Ward S; Kaltenthaler E; Cowan J; Brewer N Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497 [TBL] [Abstract][Full Text] [Related]
13. [Oral fluoropyrimidines in oncology]. González Barón M An R Acad Nac Med (Madr); 1998; 115(3):721-45; discussion 745-6. PubMed ID: 10208021 [No Abstract] [Full Text] [Related]
17. Practical considerations in the use of oral fluoropyrimidines. Hoff PM Semin Oncol; 2003 Jun; 30(3 Suppl 6):88-92. PubMed ID: 12802799 [TBL] [Abstract][Full Text] [Related]
18. Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Nies AT; Magdy T; Schwab M; Zanger UM Adv Cancer Res; 2015; 125():217-43. PubMed ID: 25640272 [TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. Baker SD; Diasio RB; O'Reilly S; Lucas VS; Khor SP; Sartorius SE; Donehower RC; Grochow LB; Spector T; Hohneker JA; Rowinsky EK J Clin Oncol; 2000 Feb; 18(4):915-26. PubMed ID: 10673535 [TBL] [Abstract][Full Text] [Related]
20. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P; J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]